Table 4.
Evaluation of dry eye syndrome using Schirmer test, conjunctiva, and cornea fluorescein staining.
| Preservative-free treatment (tafluprost) (n=30) | BAK-containing treatment (latanoprost) (n=30) | Untreated (control) (n=30) | Total (n=90) | |
|---|---|---|---|---|
| Conjunctiva staining score | ||||
| 0 | 25 (83.3%) | 18 (60.0%) | 23 (76.7%) | — |
| 1 | 5 (16.7%) | 9 (30.0%) | 7 (23.3%) | — |
| 2 | 0 (0%) | 3 (10%) | 0 (0%) | — |
|
| ||||
| Corneal staining score | ||||
| 0 | 29 (96.7%) | 23 (80.0%) | 28 (93.3%) | — |
| 1 | 1 (3.3%) | 5 (16.7%) | 2 (6.7%) | — |
| 2 | 0 (0%) | 2 (3.3%) | 0 (0%) | — |
|
| ||||
| Schirmer's test (mm/5 minutes) | 12.07∗† ± 5.80 | 8.27 ± 4.67 | 11.63∗† ± 7.64 | 10.66 ± 6.32 |
Level of significance: ∗p < 0.05; †significance of difference relative to the BAK-containing treatment (latanoprost) group.